

Case 1



65 year old male


Presented to A&E with central chest pain
Radiation to back and shortness of breath

Past medical history: Hypertension, autoimmune thyroiditis, severe depression

Medication: amlodipine, levothyroxine

Social history: Non-smoker; no excess alcohol consumption

On examination: Spleen palpable 3cm below costal margin





Investigations:

FBC: Hb 184 g/L, MCV 88, HCT 58%, WBC 14.2×10⁹/L, Neut 12.1×10⁹/L, Pt 1223×10⁹/L

Blood film: Packed with increased red cells, marked thrombocytosis, confirmed with large platelet aggregates, normal maturation to neutrophils

JAK2 V617F: Detected, variant allele frequency 64%


Ultrasound abdomen: spleen 16.6cm in maximal diameters October 2024, Dr P. Harrington GSTT



Bone marrow Trephine:

- Hypercellular marrow with 90% cellularity
- Expanded erythroid series, panmyelosis.
- Megakaryocytes appear increased and mature without atypical features
- No increase in precursors

October 2024, Dr P. Harrington GSTT





Question 1: What is the likely Diagnosis?

a. Chronic myeloid leukemia

b. Essential Thrombocythemia

c. Polycythemia vera

d. Primary myelofibrosis

e. Post ET myelofibrosis



Question 1: What is the likely Diagnosis?

a. Chronic myeloid leukemia

b. Essential Thrombocythemia

c. Polycythemia vera

d. Primary myelofibrosis

e. Post ET myelofibrosis



Question 2: Diagnostic Criteria for PV

Which of the following is major criterion as per WHO 5th Edition 2022?

a. CALR mutation

b. Subnormal Epo level

c. Megakaryocyte atypia

d. Elevated Hb >160g/l

e. JAK2 exon 12 mutation

October 2024, Dr P. Harrington GSTT



Question 2: Diagnostic Criteria for PV

Which of the following is major criterion as per WHO 5th Edition 2022?

a. CALR mutation

b. Subnormal Epo level

c. Megakaryocyte atypia

d. Elevated Hb >160g/l

e. *JAK2* exon 12 mutation



Management:

Patient taken for urgent PCI

Dual antiplatelet therapy initiated with aspirin and ticagrelor

Diagnosis of PV confirmed

WHO 20221

Major criteria:

- Elevated Hb (>16.5 g/dL in males; >16.0 g/dL in females) or elevated HCT (>49% in males; >48% in females)
- BM biopsy: hypercellularity with trilineage grown (panmyelosis), including erythroid, granulocytic and megakaryocytic proliferation with pleomorphic, mature megakaryocytes
- JAK2 or JAK2 exon 12 mutation

Minor:

٠

Subnormal EPO level



Question 3: What is appropriate initial management?

a. Pegylated interferon alpha

- b. Hydroxycarbamide
- c. Ruxolitinib
- d. Plateletpheresis
- e. Imatinib



Question 3: What is appropriate initial management?

a. Pegylated interferon alpha

b. Hydroxycarbamide

c. Ruxolitinib

d. Plateletpheresis

e. Imatinib



Clinical course:

After 12 months: Established on hydroxycarbamide, 2g OD.

Full recovery from anterior MI, cardiac function normalized.

Ongoing requirement for venesection, 450ml, every 2 months to maintain HCT < 0.45<mark>%</mark>

Development of leg ulcers, not responsive to medical management

MI, myocardial infarction



Investigations:

FBC: HB 154 g/l , MCV 87, HCT 48%, WBC 11.4 ×10⁹/l, Plt 460 ×10⁹/l

JAK2 V617F: Variant allele frequency 74%

US abdomen: spleen increased in size, 19.4cm maximal diameter





Question 4: What are the features of hydroxycarbamide resistance

ELN Consensus Criteria:

After >3 months at maximal tolerated dose or dosage of 2000mg/day

a. Development of leg ulcers

b. Platelet >600 $\times 10^{9}$ /l

c. HCT >0.5%

d. White cell count >10 $\times 10^{9}/I$



Question 4: What are the features of hydroxycarbamide resistance

ELN Consensus Criteria:

After >3 months at maximal tolerated dose or dosage of 2000mg/day

a. Development of leg ulcers

b. Platelet >600 $\times 10^{9}$ /l

c. HCT >0.5%

d. White cell count >10 x10⁹/I



Question 5: What is the most appropriate second line management?

a. Continue Hydroxycarbamide

b. Pegylated interferon alpha

c. Ruxolitinib

d. Rusfertide

e. Allogeneic stem cell transplantation



Question 5: What is the most appropriate second line management?

a. Continue Hydroxycarbamide

b. Pegylated interferon alpha

c. Ruxolitinib

d. Rusfertide

e. Allogeneic stem cell transplantation



Clinical course:

Patient started on ruxolitinib, 10mg twice daily.

After 12 months: No further venesection required

Gradual healing of leg ulcers observed

Annual screening for increased risk of non-melanomatous skin cancer

Annual vaccines to include: Covid-19, seasonal flu, varicella zoster




Investigations:

FBC: Hb 110 g/l, HCT 0.39%, WBC 6.7×10⁹/l, Neut 3.4×10⁹/l, PIt 231×10⁹/l

Repeat *JAK2* V617F: 52% VAF

US abdomen - spleen 12.6 cm in maximal diameter (>35% reduction in spleen volume)





Question 6: Which of the following is a high risk feature of PV for myelofibrotic transformation

a. White cell count >15x10⁹/I

b. Platelet count >1000<mark>×10⁹/I</mark>

c. Lower *JAK2* V617F VAF

d. Prior Hydroxycarbamide treatment



Question 6: Which of the following is a high risk feature of PV for myelofibrotic transformation

a. White cell count >15x<mark>10⁹/I</mark>

b. Platelet count >1000<mark>×10⁹/I</mark>

c. Lower JAK2 V617F VAF

d. Prior Hydroxycarbamide treatment



Case 2




65-year-old woman diagnosed with Essential Thrombocythemia in 2015

CAL-R type 1 identified

No prior history of thrombosis

Management with hydroxycarbamide 500mg 0D with complete hematologic response

3 years after diagnosis – seen in clinic complaining of abdominal pain.






Investigations:

FBC: Hb 114 g/l, MCV 102 fl, HCT 0.31<mark>%</mark>, WBC 14.1<mark>×10⁹/l</mark>, PIt 120<mark>×10⁹/l</mark>

Bone marrow biopsy: extensive fibrosis with clustered megakaryocytes Reticulin stain shows grade 3 fibrosis

US abdomen: spleen 21cm in maximal diameter





Question 1: Which of the following is associated with increased risk of myelofibrotic progression in ET?

a. *CALR* type 2

b. *JAK2* VAF >30%

c. MPL

d. Female sex

e. Age >50 years



Question 1: Which of the following is associated with increased risk of myelofibrotic progression in ET?

a. *CALR* type 2

b. *JAK2* VAF >30%

c. MPL

d. Female sex

e. Age >50 years



Question 2: Which of the following is a major or minor criteria for post ET myelofibrosis?

a. Platelet >1500<mark>×10⁹/I</mark>

b. Increased serum lactate dehydrogenase

c. WBC >10<mark>×10⁹/I</mark>

d. *JAK2* VAF >35%

e. Dysplastic blood film



Question 2: Which of the following is a major or minor criteria for post ET myelofibrosis?

a. Platelet >1500

b. Increased serum lactate dehydrogenase

- c. WBC >10<mark>×10⁹/I</mark>
- d. *JAK2* VAF >35%
- e. Dysplastic blood film




Clinical Course:

DIPPS plus: Intermediate 1

Management: active surveillance

Close monitoring with clinic review every 3 months

Ongoing symptom burden from splenomegaly – spleen now 24cm MPN 10 TSS: 42



Repeat blood film: myeloid blasts: 2%



Question 3: Which of the following is an adverse risk factor in the DIPPS Plus prognostic score?

a. Age >60

b. WBC >20x10⁹/I

c. Platelets <100<mark>×10⁹/I</mark>

d. +9 on cytogenetics

e. ASXL1 mutation



Question 3: Which of the following is an adverse risk factor in the DIPPS Plus prognostic score?

a. Age >60

b. WBC >20x10⁹/I

c. Platelets <100<mark>×10⁹/l</mark>

d. +9 on cytogenetics

e. ASXL1 mutation



Question 4: Most appropriate treatment option at this point?

a. Hydroxycarbamide

b. Pegylated interferon

c. Splenectomy

d. Allogeneic stem cell transplantation

e. Ruxolitinib



Question 4: Most appropriate treatment option at this point?

a. Hydroxycarbamide

b. Pegylated interferon

c. Splenectomy

d. Allogeneic stem cell transplantation

e. Ruxolitinib



Clinical Course

Patient started ruxolitinib 15mg twice daily

Dose up-titrated to maximal dose of 25mg BD

After 12 months: Spleen reduced to 12.7cm MPN-10 TSS: 18





Investigations

- FBC: Hb 82g/I, MCV 81 <mark>fI</mark>, WBC 16.1<mark>×10⁹/I</mark>, Neut 12.3<mark>×10⁹/I</mark>, PIt 125<mark>×10⁹/I</mark>
- Blood film: 1% blasts
- Serum Epo: 520 IU/L
- Myeloid gene panel analysed: no additional mutations
- MIPPS 70 v2 score: Low Risk
- MPN 10 TSS: 28
- rHuEPo added and uptitrated to 40,000 IU weekly



Question 5: Which of the following is an adverse risk factor in the MIPPS 70 plus version 2 prognostic score?

a. Age >60

b. WCC >20<mark>×10⁹/I</mark>

c. Blasts >1%

d. Absence of *CALR* type 1

e. U2AF1 s34 mutation



Question 5: Which of the following is an adverse risk factor in the MIPPS 70 plus version 2 prognostic score?

a. Age >60

b. WCC >20<mark>×10⁹/I</mark>

c. Blasts >1%

d. Absence of *CALR* type 1

e. U2AF1 s34 mutation



Question 6: What is the most appropriate treatment option at this point

a. Fedratinib

b. Ruxolitinib and danazol

c. Increased dosage rHuEpo

d. Momelotinib

e. Allogeneic stem cell transplant



Question 6: What is the most appropriate treatment option at this point

a. Fedratinib

b. Ruxolitinib and danazol

c. Increased dosage rHuEpo

d. Momelotinib

e. Allogeneic stem cell transplant



Clinical Course

- Momelotinib started 200mg 0D
- After 3 months:
- FBC: Hb 108 g/I, MCV 81 <mark>fl</mark>, WBC 12.3<mark>×10⁹/I</mark>, PIt 623<mark>×10⁹/I</mark>
- No further PRC transfusion required.
- Notable improvement in fatigue
- MPN 10 TSS: 16
- rHuEpo reduced and discontinued 6 months following initiation



Clinical Course

- Patient developed heightened sensation and paraesthesia in stocking distribution
- Nerve conduction studies confirmed axonal peripheral neuropathy
- Momelotinib dosage reduced to 150mg daily
- Hematologic response maintained with no PRC transfusion requirements
- Notable reduction in peripheral neuropathy with dose modification burden